Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,762
datasets available to search
ShareScore release 0.9.0
Dataset results
3,762 results for “Combination treatment”
Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for RAS wild-type metastatic colorectal cancer patients based on the TAILOR trial
<p><b>Objectives</b> Cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) is superior to FOLFOX-4 alone as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer (wt mCRC), with significantly improved survival benefit by TAILOR, an open-label, randomized, multicentre, phase III trial. Nevertheless, the cost-effectiveness of these two regimens remains uncertain. The following study aims to determine whether cetuximab combined with FOLFOX-4 is a cost-effective strategy for specific RAS wt mCRC patients in China.</p> <p><b>Design</b> A combined decision tree and Markov model with three health states (stable, progressive and dead) was constructed to simulate a hypothetical cohort of patients with RAS wt mCRC. The health outcomes and utility scores were derived from the TAILOR trial and previously published sources, respectively. Costs were calculated with reference to the Chinese societal perspective. A lifetime horizon was used. Univariate and probabilistic sensitivity analyses were carried out to test the robustness of the model results.</p> <p><b>Participants</b> The included patients were newly diagnosed Chinese patients with fully RAS wt mCRC. <b>Interventions</b> Either cetuximab plus FOLFOX-4 or FOLFOX-4 alone as a first-line treatment.</p> <p><b>Main outcome measures</b> The primary outcomes are costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs).</p> <p><b>Results</b> Baseline analysis showed that the addition of cetuximab increased the QALYs by 0.383, while an increase of $62,947 was observed in relation to FOLFOX-4 chemotherapy. This led to an incremental cost-effectiveness ratio (ICER) of $164,044/QALY. Sensitivity analysis showed that across the wide variation in parameters, the ICER exceeded the willingness-to-pay threshold of $28,106/QALY, which was three times the per capita GDP in China.</p> <p><b>Conclusions</b> Despite the survival benefit, cetuximab combined with FOLFOX-4 is not a cost-effective treatment for the first line treatment of patients with RAS wt mCRC in China.</p>
Data from: Phenotype uniformity in combined-stress environments has a different genetic architecture than in single-stress treatments
For crop production it is desirable for the mapping between genotype and phenotype to be consistent, such that an optimized genotype produces uniform sets of individual plants. Uniformity is strongly selected in breeding programs, usually automatically, as harvest equipment eliminates severely non-uniform individuals. Uniformity is genetically controlled, is known to be increased by interplant competition, and is predicted to increase upon abiotic stress. We mapped maize loci controlling genotype by environment interaction in plant height uniformity. These loci are different than the loci controlling mean plant height. Uniformity decreases upon combining two abiotic stresses, with alleles conferring greater uniformity in a single stress showing little improvement in a combined stress treatment. The maize B73 and Mo17 inbreds do not provide segregating alleles for improvement in plant height uniformity, suggesting that the genetic network specifying plant height has a past history of selection for robustness.
Tailoring the adhesion of electrophoretic chitosan/bioactive glass coatings by the combined surface pre-treatments of Ti substrates
<p>This record contains all files generated in the preparation process of the following publication: </p> <p>Agnieszka Kowalczyk, Agata Sotniczuk, Donata Kuczyńska-Zemła, Jarosław Pura, Zhiyan Xu, Aldo R. Boccaccini, Halina Garbacz,<br>"Tailoring the adhesion of electrophoretic chitosan/bioactive glass coatings by the combined surface pre-treatments of Ti substrates", submitted to Surface and Coatings Technology.</p> <p>Designations: <br>Ti_G2 - Titanium Grade 2 <br>G - sample grinded on #600 grit abrasive paper<br>SP - sample shot-peened with 90-150 µm shots, under pressure of 0.5 MPa<br>E - sample etched <br>SP+E_HF - sample shot-peened with 90-150 µm shots, under the pressure of 0.5 MPa and etched in the hydrofluoric solution <br>SP+E_NaOH - sample shot-peened with 90-150 µm shots, under the pressure of 0.5 MPa and etched in the sodium hydroxide solution<br>SP+E_HF_NaOH - sample shot-peened with 90-150 µm shots, under the pressure of 0.5 MPa and etched first in the hydrofluoric solution and then in sodium hydroxide <br>EPD - samples coated with chitosan/bioglass coating<br>ADH - samples coated with chitosan/bioglass coating after conducted adhesion test<br>SBF - samples after bioactivity test in Simulated Body Fluid (SBF) solution<br>SEM - Scaning Electron Microscopy <br>EDS - Energy Dispersive Spectroscopy</p> <p>Folders content:</p> <ul> <li>Corrosion - contains files with data of corrosion resistance, obtained during electrochemical tests</li> <li>FTIR - contains files obtained from Fourier Transform Infrared Spectroscopy analysis of chitosan/bioglass coating</li> <li>Roughness - contains files from topography analysis obtained using optical profilometer for various scan areas</li> <li>SEM - contains folders with images of samples surfaces from Scanning Electron Microscopes. Subfolders: <ul> <li>Adhesion - contains SEM images of samples coated with chitosan/bioglass coatings after tape test</li> <li>Bioactivity test - contains SEM images and EDS analysis of samples coated with chitosan/bioglass coatings after bioactivity test in SBF</li> <li>Coatings - contains SEM images of chitosan/bioactive glass coatings deposited on different substrates</li> <li>Substrate - contains SEM images of titanium substrate after various surface modifications</li> </ul> </li> <li>Wettability - contains files with data obtained from wettability tests</li> <li>XRD - contains files with data obtained from X-ray spectroscopy analysis</li> </ul> <p>This research was supported financially by the National Science Centre, Poland under the grant OPUS 23 [2022/45/B/ST5/03398].</p> <p> </p>
Comparison of Clinical Outcomes Between Liposuction and Liposuction in Combination with Microsurgery for Lymphedema Treatment: A Proportions Meta-Analysis
<p>Funnel plots for heterogenicity of each subgroup analysis. a) Excess Volume Reduction Lipo subgroup. b) Excess Volume Reduction Lipo+Micro subgroup. c) Decrease/reduction in post-operative use of compression garment subgroup Lipo. d) Decrease/reduction in post-operative use of compression garment subgroup Lipo+Micro. e) Post-operative reduction of erysipelas/cellulitis subgroup Lipo. f) Post-operative reduction of erysipelas/cellulitis subgroup Lipo+Micro.</p>
The effects of antibiotic combination treatments on Pseudomonas aeruginosa tolerance evolution and coexistence with Stenotrophomonas maltophilia
<p><em>Pseudomonas aeruginosa</em> bacterium is a common pathogen of Cystic Fibrosis (CF) patients due to its ability to evolve resistance to antibiotics during treatments. While <em>P. aeruginosa</em> resistance evolution is well characterised in monocultures, it is less well understood in polymicrobial CF infections. Here, we investigated how exposure to ciprofloxacin, colistin, or tobramycin antibiotics, administered at sub-MIC doses alone and in combination, shaped the tolerance evolution of <em>P. aeruginosa</em> (PAO1 lab and clinical CF LESB58 strains) in the absence and presence of a commonly co-occurring species, <em>Stenotrophomonas maltophilia</em>. Increases in antibiotic tolerances were primarily driven by the presence of that antibiotic in the treatment. We observed a reciprocal cross-tolerance between ciprofloxacin and tobramycin, and when combined these antibiotics selected increased MICs for all antibiotics. Though the presence of <em>S. maltophilia</em> did not affect the tolerance or the MIC evolution, it drove <em>P. aeruginosa</em> into extinction more frequently in the presence of tobramycin due to its relatively greater innate tobramycin tolerance. In contrast, <em>P. aeruginosa</em> dominated and drove <em>S. maltophilia</em> extinct in most other treatments. Together, our findings suggest that besides driving high-level antibiotic tolerance evolution, sub-MIC antibiotic exposure can alter competitive bacterial interactions, leading to target pathogen extinctions in multi-species communities.</p>
Comparative Efficacy and Safety of Sitagliptin Phosphate Combined with Gliclazide Sustained-Release Tablets Versus Metformin in Treatment-Naïve Patients with Type 2 Diabetes Mellitus and Glucotoxicity: A Single-Center, Prospective, Randomized Controlled Non-Inferiority Study
<p>This dataset supports the manuscript titled "Comparative Efficacy and Safety of Sitagliptin Phosphate Combined with Gliclazide Sustained-Release Tablets Versus Metformin in Treatment-Naïve Patients with Type 2 Diabetes Mellitus and Glucotoxicity: A Single-Center, Prospective, Randomized Controlled Non-Inferiority Study." The study aims to compare the efficacy and safety of sitagliptin phosphate combined with gliclazide sustained-release tablets against metformin in treatment-naïve patients with type 2 diabetes mellitus and glucotoxicity. Data include clinical measurements, laboratory test results, and adverse event records collected throughout the trial period. Statistical analyses were conducted to assess non-inferiority between the two treatment groups. This dataset provides valuable insights for researchers interested in diabetes management, pharmacotherapy, and randomized controlled trials.</p>
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
ClinicalTrials.gov study NCT07330596. IPD Sharing: NO. Countries: 1. Publications: 9.
Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-
ClinicalTrials.gov study NCT02613403. IPD Sharing: YES. Countries: 0. Publications: 1.
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
ClinicalTrials.gov study NCT04675866. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
ClinicalTrials.gov study NCT02436707. IPD Sharing: YES. Countries: 1. Publications: 1.
Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure
ClinicalTrials.gov study NCT01763099. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
ClinicalTrials.gov study NCT06831175. IPD Sharing: NO. Countries: 1. Publications: 10.
Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria
ClinicalTrials.gov study NCT00519467. IPD Sharing: YES. Countries: 2. Publications: 2.
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Rec
ClinicalTrials.gov study NCT02770378. IPD Sharing: NO. Countries: 1. Publications: 2.
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
ClinicalTrials.gov study NCT02272478. IPD Sharing: Not stated. Countries: 2. Publications: 0.
A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
ClinicalTrials.gov study NCT01735968. IPD Sharing: NO. Countries: 8. Publications: 1.
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma
ClinicalTrials.gov study NCT00050102. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C
ClinicalTrials.gov study NCT00088504. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Optimal Treatment of Plantar Fasciitis: Physical Training, Glucocorticoid Injections or a Combination Thereof.
ClinicalTrials.gov study NCT01994759. IPD Sharing: Not stated. Countries: 1. Publications: 11.
The Detection of CTCs in Patients With Pancreatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment.
ClinicalTrials.gov study NCT02406846. IPD Sharing: Not stated. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.